{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:47:05Z","timestamp":1783986425786,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"ROCHE","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.breast.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T20:26:04Z","timestamp":1571343964000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study"],"prefix":"10.1016","volume":"49","author":[{"given":"Jean-Philippe","family":"Jacquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Uwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Savignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Solub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassera","family":"Chalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Pibre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-8370","authenticated-orcid":false,"given":"Yazid","family":"Belkacemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.breast.2019.10.002_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"The Oncologist"},{"key":"10.1016\/j.breast.2019.10.002_bib2","author":"National Comprehensive Cancer Network"},{"issue":"Suppl 5","key":"10.1016\/j.breast.2019.10.002_bib3","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2019.10.002_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0032-1321831","article-title":"Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen","volume":"62","author":"Bittner","year":"2012","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.breast.2019.10.002_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A\u00a0recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J\u00a0Control Release"},{"issue":"10","key":"10.1016\/j.breast.2019.10.002_bib7","doi-asserted-by":"crossref","first-page":"962e70","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.breast.2019.10.002_bib8","doi-asserted-by":"crossref","first-page":"1979e87","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2019.10.002_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2019.10.002_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/annonc\/mdu524","article-title":"Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study","volume":"26","author":"Jackisch","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2019.10.002_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.03.087","article-title":"HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up","volume":"62","author":"Jackisch","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2019.10.002_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2017.08.019","article-title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","volume":"86","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2019.10.002_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.05.010","article-title":"Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study\u2019s primary analysis of 2573 patients","volume":"82","author":"Gligorov","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2019.10.002_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2019.10.002_bib15","article-title":"Real-world data on health-related quality of life assessment in patients with breast cancer receiving subcutaneous trastuzumab","volume":"12","author":"Syrios","year":"2018","journal-title":"Breast Cancer (Auckl)"},{"issue":"10","key":"10.1016\/j.breast.2019.10.002_bib16","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.12968\/bjon.2019.28.10.S15","article-title":"Intravenous versus subcutaneous trastuzumab: an economic and patient perspective","volume":"28","author":"Mitchell","year":"2019","journal-title":"Br J Nurs"},{"issue":"10","key":"10.1016\/j.breast.2019.10.002_bib17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2019.10.002_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2017.05.009","article-title":"Patients\u2019 preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study","volume":"82","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761930565X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097761930565X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:41:00Z","timestamp":1760776860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097761930565X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":17,"alternative-id":["S096097761930565X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2019.10.002","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}